A new trading day began on Friday, with BioXcel Therapeutics Inc (NASDAQ: BTAI) stock price up 8.12% from the previous day of trading, before settling in for the closing price of $0.32. BTAI’s price has ranged from $0.32 to $4.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 53.60% over the past five years. Meanwhile, its annual earnings per share averaged 72.25%. With a float of $41.10 million, this company’s outstanding shares have now reached $42.46 million.
Let’s look at the performance matrix of the company that is accounted for 74 employees. In terms of profitability, gross margin is 4.13%, operating margin of -3295.61%, and the pretax margin is -3119.33%.
BioXcel Therapeutics Inc (BTAI) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 17.18%, while institutional ownership is 11.89%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.25% per share during the next fiscal year.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Here are BioXcel Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.15, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.56 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics Inc (NASDAQ: BTAI) saw its 5-day average volume 1.09 million, a positive change from its year-to-date volume of 0.83 million. As of the previous 9 days, the stock’s Stochastic %D was 7.82%. Additionally, its Average True Range was 0.06.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 4.93%, which indicates a significant decrease from 15.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 112.32% in the past 14 days, which was higher than the 99.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5364, while its 200-day Moving Average is $1.2963. Nevertheless, the first resistance level for the watch stands at $0.3567 in the near term. At $0.3724, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4007. If the price goes on to break the first support level at $0.3127, it is likely to go to the next support level at $0.2844. The third support level lies at $0.2687 if the price breaches the second support level.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
With a market capitalization of 18.29 million, the company has a total of 42,748K Shares Outstanding. Currently, annual sales are 1,380 K while annual income is -179,050 K. The company’s previous quarter sales were 210 K while its latest quarter income was -13,650 K.
